These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18290932)

  • 1. Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapy.
    Jenner A; Scott A
    Sociol Health Illn; 2008 Mar; 30(2):197-216. PubMed ID: 18290932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The experience of interferon-based treatments for hepatitis C infection.
    Hopwood M; Treloar C
    Qual Health Res; 2005 May; 15(5):635-46. PubMed ID: 15802540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The therapy of hepatitis C in the failure of interferon].
    Hermann R; Maier KP
    Dtsch Med Wochenschr; 1997 Aug; 122(34-35):1049-54. PubMed ID: 9312461
    [No Abstract]   [Full Text] [Related]  

  • 4. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The combination administration of interferon in viral hepatitis].
    Zhao GD; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):5-7. PubMed ID: 21272449
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and costs of care in hepatitis C: combination therapy scores again.
    Koff RS
    Am J Gastroenterol; 2000 Jun; 95(6):1392-3. PubMed ID: 10894568
    [No Abstract]   [Full Text] [Related]  

  • 8. Negotiating treatment for hepatitis C: interpersonal alignment in the clinical encounter.
    Körner H
    Health (London); 2010 May; 14(3):272-91. PubMed ID: 20427634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A la carte interferon for hepatitis C?
    Marcellin P; Benhamou JP; Heathcote J; Bismuth H; Desmet V; Guardia J; Lok A; Buschenfeld KH; Pagliaro L; Paumgartner G; Rodes J; Sherlock S
    Hepatology; 2000 Sep; 32(3):678-9. PubMed ID: 10991636
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic factors predicting response to interferon treatment for viral hepatitis C.
    Stärkel P
    Gut; 2008 Apr; 57(4):440-2. PubMed ID: 18334658
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
    Freedman K; Nathanson J
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of HIV/hepatitis C virus coinfection.
    Pozza R
    J Am Acad Nurse Pract; 2008 Oct; 20(10):496-505. PubMed ID: 19128345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living with hepatitis C and treatment: the personal experiences of patients.
    Sgorbini M; O'Brien L; Jackson D
    J Clin Nurs; 2009 Aug; 18(16):2282-91. PubMed ID: 19583661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly acquired hepatitis C--many hurdles from diagnosis until treatment initiation.
    Wiegand J
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1782-4. PubMed ID: 19120870
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe pruritus after completing pegylated interferon for hepatitis C.
    Hoffman CJ; Ray SC
    AIDS Read; 2008 Nov; 18(11):562-5. PubMed ID: 19062400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.